Bicycle Therapeutics plc (Nasdaq: BCYC)

https://www.bicycletherapeutics.com

LinkedIn: https://linkedin.com/company/bicylce-therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. *

	Start	2019-08-08 reorganised before

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Blocks A & B Portway Building Granta Park, Great Abington
	City	CV21 6GP Cambridge
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2023-12-31)
	Currency	USD
	Annual sales	25,859,000 (revenue, consolidated (2023) 2023-12-31)
	Profit	-168,578,000 (2023-12-31)
	Cash	526,423,000 (2023-12-31)

		* Document for »About Section«: Bicycle Therapeutics plc. (6/23/23). "Press Release: Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer". Cambridge & Boston, MA.

		Record changed: 2025-07-17

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Bicycle Therapeutics (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com